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In this review, we discuss how changes in the intragraft microenvironment serve to pro-
mote or sustain the development of chronic allograft rejection. We propose two key
elements within the microenvironment that contribute to the rejection process.The ﬁrst is
endothelial cell proliferation and angiogenesis that serve to create abnormal microvas-
cular blood ﬂow patterns as well as local tissue hypoxia, and precedes endothelial-to-
mesenchymal transition.The second is the overexpression of local cytokines and growth
factors that serve to sustain inﬂammation and, in turn, function to promote a leukocyte-
induced angiogenesis reaction. Central to both events is overexpression of vascular
endothelial growth factor (VEGF), which is both pro-inﬂammatory and pro-angiogenic, and
thus drives progression of the chronic rejection microenvironment. In our discussion, we
focus on how inﬂammation results in angiogenesis and how leukocyte-induced angiogen-
esis is pathological. We also discuss how VEGF is a master control factor that fosters
the development of the chronic rejection microenvironment. Overall, this review provides
insight into the intragraft microenvironment as an important paradigm for future direction
in the ﬁeld.
Keywords:endothelialcell,microvascularinjury,angiogenesis,vascularendothelialgrowthfactor,hypoxia,allograft
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GENERAL OVERVIEW
In an endothelial cell (EC)-based model, the initiation of inﬂam-
mation within an allograft results from the activation of donor
ECs responding to pro-inﬂammatory cytokines released from res-
ident macrophages in response to hypoxia (Cotran, 1994; Briscoe
et al., 1998; Denton et al., 2000; Pober and Sessa, 2007; Ingulli
et al., 2009). Graft EC also respond to cytokines and growth
factors produced in association with alloimmune cellular and
humoral targeting of the graft (Pober et al., 1996; Valujskikh and
Heeger, 2003; Zhang and Reed, 2009; Halloran et al., 2010; Sis
and Halloran, 2010), as well as by factors produced by inﬁltrat-
ing mononuclear cells that are characteristic of chronic rejection
(LibbyandPober,2001).Theinducedexpressionofadhesionmol-
ecules and chemokines by donor EC results in the recruitment of
leukocytes into the graft, whereas the expression of MHC class I
and II molecules on donor EC is critical for the local presenta-
tion of alloantigen to inﬁltrating effector/memory lymphocytes
(Briscoe and Sayegh, 2002; Kreisel et al., 2002; Pober and Sessa,
2007). These events set the stage for an intragraft microenviron-
ment that sustains donor-directed alloimmune inﬂammation and
the development of chronic rejection.
In this review, we focus on how the integrity of the vascular
endothelium is critical for a microenvironment that sustains allo-
graft function. In vascularized solid organ allografts, such as the
kidney, early ischemia–reperfusion results in profound injury to
the microvasculature (Bishop et al., 1989; Vos and Briscoe, 2002;
Woywodt et al., 2003; Reinders et al., 2006; Aydin et al., 2007;
Contreras and Briscoe, 2007; Rabelink et al., 2007; Mayer, 2011).
Furthermore, the degree of injury and microvascular EC loss at
early times post transplantation can be predictive of long-term
graft survival (Bishop et al.,1989; Choi et al.,2000; Fine and Nor-
man,2008; Mayer,2011; Steegh et al.,2011) .I n d e e d ,i ti sr e p o rt e d
that the sequential loss of peritubular capillaries, starting as early
as 3months post renal transplantation predicts the development
of interstitialﬁbrosisandtubularatrophy(IFTA)andlaterchronic
rejection (Steegh et al., 2011). It is proposed that the loss of the
intrarenalmicrovasculatureresultsinimpaireddeliveryof oxygen
and nutrients to the renal tubules, which in turn contributes to
local tissue ischemia, tubular dropout, and cell death (Kang et al.,
2002; Reinders et al., 2006; Contreras and Briscoe, 2007; Rabelink
et al., 2007; Fine and Norman, 2008; Mayer, 2011). Thus, the ini-
tial loss of microvessels/peritubular capillaries may be a primary
factor in the development of ﬁbrosis and chronic renal disease
(Kang et al., 2002; Reinders and Briscoe, 2002; Contreras and
Briscoe, 2007; Mayer, 2011). Pharmacologic therapy which can
protect microvascular integrity at early times post transplantation
has potential to improve long-term graft survival (Johnson et al.,
2006; Nakao et al., 2006; Aydin et al., 2007; Rabelink et al., 2007;
Briscoe and Pal, 2008; Leonard et al., 2008; Hanto et al., 2010).
If early protection and repair is not accomplished, then ongoing
local ischemia will result in cellular atrophy, and chronic allograft
disease will be inevitable.
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However, it is underappreciated that inﬂammatory inﬁltrates
also cause EC proliferation, a process called leukocyte-induced
angiogenesis (Auerbach and Sidky, 1979; Cotran, 1994). In addi-
tion, the binding of alloantibodies to the graft vascular endothe-
lium can result in EC activation and a proliferative response
(Zhang and Reed, 2009). As will be discussed below, this abnor-
mal or pathological angiogenesis response may be associated with
local tissue hypoxia, and thus precedes later hypoxic tissue injury
(Babu et al.,2007; Contreras and Briscoe,2007; Goel et al.,2011).
If EC proliferation occurs at later times post transplantation in
association with pericyte loss, microvessels become disorganized
and endothelial-to-mesenchymal transition (EndMT) may occur.
This results in collagen deposition and tissue ﬁbrosis (Schor et al.,
1995; Humphreys et al., 2010; Medici et al., 2010). Central to all
these events is the expression of vascular endothelial growth fac-
tor (VEGF),which is both pro-angiogenic and pro-inﬂammatory,
and thus drives progression of the chronic rejection microenvi-
ronment (Reinders et al.,2006). Here,we discuss a new paradigm,
whereby local tissue hypoxia and overexpressed intragraft VEGF
are key features of a microenvironment that determine the devel-
opment of chronic rejection. Cartoons illustrating this paradigm
are shown in Figures 1 and 2.
MICROVASCULAR PATTERNING AND THE INTRAGRAFT
MICROENVIRONMENT
Angiogenesis, the generation of new blood vessels from pre-
existing ones, is a complex process involving the degradation of
the vascular basement membrane and surrounding extracellular
matrix as well as EC proliferation and migration (Cotran, 1994;
Folkman, 1995a,b; Brown et al., 1997; Carmeliet and Jain, 2000;
Ferrara and Kerbel, 2005; Goel et al., 2011). The creation of new
bloodvesselsiscriticalfornormalorgangrowthanddevelopment
anditisarequirementfornormalwoundhealingandtissuerepair
(Cotran,1994; Majno,1998). In all of these biological conditions,
angiogenesis is tightly regulated in a tissue speciﬁc manner, such
that the microvascular bed provides tissues with their nutritive
and oxygen demands in a manner that is sufﬁcient for normal
physiological processes. However, angiogenesis is also character-
istic of many disease states, and is well-established to occur in
association with cell-mediated immune responses (Cotran, 1994)
andchronicinﬂammatorydiseases(FolkmanandBrem,1992;Fer-
rara and Alitalo, 1999; Ezaki et al., 2001), notably inﬂammatory
bowel disease (Kanazawa et al., 2001), arthritis (Walsh and Pear-
son, 2001), chronic asthma (Detoraki et al., 2010), and chronic
allograft rejection (Tanaka et al., 1994;Moulton et al., 1999; Rein-
FIGURE 1 | Cartoon illustrating the interplay between alloimmunity and
the intragraft microvasculature. (A) Following transplantation, alloimmune
inﬂammatory responses target the graft vascular endothelium resulting in the
destruction of microvessels, which in turn leads to local hypoxia and tissue
injury. (B) Alloimmune inﬂammatory responses may also stimulate
endothelial cell proliferation and promote leukocyte-induced angiogenesis
within allografts.The local delivery of the pro-inﬂammatory and
pro-angiogenic factor vascular endothelial growth factor (VEGF) is central to
this response. Pathological leukocyte-induced angiogenesis results in the
formation of abnormal networks of capillaries that lead to chaotic blood ﬂow
patterns and paradoxically results in local hypoxia.Thus, local tissue hypoxia
is the end result of acute events and direct targeting of the graft endothelial
cells (A) as well as inﬂammation and the associated leukocyte-induced
angiogenesis (B).
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FIGURE 2 | Cartoon illustrating a mechanism of tissue ﬁbrosis associated
with allograft rejection. During inﬂammation, pathological angiogenesis,
and/or local hypoxia can lead to pericyte loss. Under normal conditions
homeostatic repair occurs under the inﬂuence of protective growth and
survival factors. In contrast, when the inﬂammatory microenvironment is
sustained, the loss of pericytes serves as a precedent for
endothelial-to-mesenchymal transition (EndMT), where endothelial cells
become denuded from their basement membrane and migrate along with
pericytes into the surrounding tissue. Although still under debate, it is
reported that the presence ofTGFβ, inﬂammatory cytokines, and hypoxia
enables dissociated pericytes and/or endothelial cells to dedifferentiate into
collagen-secreting ﬁbroblasts, which in turn results in ﬁbrosis and scarring.
ders and Briscoe, 2002; Denton et al., 2004; Babu et al., 2007).
In disease processes, the neoangiogenesis response occurs in an
abnormalanddisorganizedmanner.Insomechronicdiseasecon-
ditions,suchasarthritisandchronicasthma,itcanbeuncontrolled
(Walsh and Pearson,2001; Detoraki et al.,2010). Solid tumors are
a prototype example where angiogenesis can be abnormal and
pathological (Fukumura and Jain, 2007; Jain, 2008; Goel et al.,
2011).Inthisdisease,localtissuehypoxiadrivestheproductionof
angiogenesis factors,notablyVEGF. This in turn elicits a powerful
neovascular response (Brown et al., 1997; Goel et al., 2011). Since
newly formed vessels are irregular in size with random branching
patterns, the associated blood ﬂow within the entire microvascu-
lar tree becomes abnormal and shunting occurs throughout the
tissue (Jain, 2008; Goel et al., 2011). In this manner, some areas
of the tissue have potential for increased blood ﬂow and have
adequate oxygenation. In contrast, other areas have decreased or
aberrant blood ﬂow which results in local tissue hypoxia. This
latter event further drives the expression of hypoxia-inducible
angiogenesisfactors,includingVEGF,suchthatthecyclicalprocess
is sustained. It is proposed that these events may also occur in
association with chronic kidney disease as well as within kidney
allografts in association with chronic rejection (Choi et al., 2000;
Reinders et al., 2006; Contreras and Briscoe, 2007; Mayer, 2011;
Figure 1). Therefore, local tissue hypoxia may occur as a result of
both initial targeting and loss of microvessels (Figure 1A), or as a
resultof leukocyte-inducedangiogenesis(Figure1B).Wepropose
that once an abnormal pattern of blood vessels develop within
the intragraft microenvironment, it likely serves to elicit local tis-
sue hypoxia as well as to induce VEGF expression, analogous to
that described in tumors (Goel et al., 2011). We hypothesize that
these events sustain inﬂammation and the progression of chronic
rejection.
LEUKOCYTE-INDUCED ANGIOGENESIS: A PATHOLOGICAL
RESPONSE THAT SUSTAINS INTRAGRAFT INJURY
Leukocyte-induced angiogenesis was initially described following
the local injection of spleen cells into the skin of nude mice (Sidky
and Auerbach,1975;Auerbach and Sidky,1979). In these original
studies, it was noted that the reaction did not occur following the
injection of syngeneic spleen cells,but it was dose-dependent and
reproduciblefollowingtheintradermalinjectionofallogeneiccells
(Auerbach and Sidky, 1979). Subsequently, it was demonstrated
thatthisleukocyte-inducedangiogenesisreactionwasmediatedby
CD4+ T lymphocytes (Kaminski and Auerbach, 1988), which we
now understand to be critical for the initiation of the alloimmune
inﬂammatory response (Ingulli et al., 2009). Thus, while not the
intention of these studies, this model clearly indicates that alloac-
tivated leukocytes are potent for the production of angiogenesis
factors.Indeed,itisnowknownthatbothmonocyte/macrophages
(Koch et al.,1986; Leibovich andWiseman,1988; Polverini,1997)
andactivatedTcells(Freemanetal.,1995;Melteretal.,2000;Mor
et al.,2004) secrete angiogenesis factors,includingVEGF,which is
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a central mediator of the leukocyte-induced reaction (Leibovich
et al., 1987; Giraudo et al., 1998; Reinders et al., 2006). Other
factors including TNF-α (63), TGF-β, and nitric oxide (Wiseman
et al., 1988; Leibovich et al., 1994) may also elicit the response.
Therefore, angiogenesis may result from the local production of
distinct factors, or via cytokine- and cell-mediated responses that
increase local concentrations of VEGF. This interplay between
cell-mediated immune reactions and the local delivery of TGF-β
and VEGF by monocyte/macrophages have resulted in the devel-
opment of paradigms to explain how angiogenesis and ﬁbrosis
are characteristic of chronic inﬂammatory disease states (Cotran,
1994; Brown et al.,1995; Freeman et al.,1995; Sharma et al.,1996;
Inoue et al., 1998; Majno, 1998; Pilmore et al., 1999; Jain et al.,
2000, 2002; Ezaki et al., 2001; Kanazawa et al., 2001; Mannon,
2006; Booth and Bishop,2010).
In our own studies, we evaluated recipient angiogenesis using
a humanized SCID mouse (huSCID) model of rejection (Moul-
ton et al., 1999). Human foreskin was transplanted onto SCID
mice and was found to engraft after 4–6weeks. Functional ves-
sels and vascular networks within the healed human skin were
derived from both human and mouse EC (Briscoe et al., 1999).
The subsequent adoptive transfer of human peripheral blood
leukocytes into the mouse resulted in human leukocytic inﬁltrates
within the engrafted human skin but not within the adjacent
mouse skin, as evaluated by videomicroscopy and by immuno-
histochemistry (Briscoe et al., 1999; Moulton et al., 1999). After
2–3days,inﬁltrateswerepresentwithingraftsbyvideomicroscopy,
and by 7days, inﬁltrates were notable by immunohistochem-
istry; by day 14, cellular inﬁltrates were profound within grafts.
In our analyses, we also found a notable angiogenesis response
that was spatially associated with leukocytic inﬁltrates within
the human skins. The angiogenesis response occurred at early
time points, typically on day 3–5 by videomicroscopy and on
day 7 by immunohistochemistry (Moulton et al., 1999). Notably,
the response preceded the development of marked inﬁltrates,
which were ultimately associated with microvascular destruction.
Therefore, we propose that local tissue hypoxia was not the pri-
mary stimulus for the initiation of the angiogenesis response
within these allografts. Rather, we believe that the angiogen-
esis reaction was initiated by factors produced by inﬁltrating
leukocytes in a similar manner as previously noted by Auer-
bach and Sidky (1979) in their model of leukocyte-induced
angiogenesis.
More recently, Babu et al. (2007) found a similar neovas-
cularization reaction in their analysis of rejecting tracheal allo-
grafts. Although they did not characterize this response in great
detail, their studies illustrated prominent angiogenesis in grafts
on days 4-, 6-, and 8-post transplantation. Similar to our studies
(Moulton et al., 1999; Contreras and Briscoe, 2007), they noted
that it did not persist and completely disappeared by day 10–12
following transplantation in association with fulminant rejec-
tion. However, these authors also evaluated tissue oxygenation
within the graft. Surprisingly, rather than ﬁnding that oxygena-
tion was normal at sites of neovascularization, they observed that
tissue pO2 decreased in day 4–6 allografts when the leukocyte-
induced angiogenesis reaction was prominent (Babu et al., 2007).
Theirobservationsindicatethat,contrarytoexpectations,hypoxia
occurs within allografts prior to microvascular destruction, and
it is associated with the presence of leukocyte-induced angio-
genesis. This observation is consistent with extensive studies by
RakeshJainsgroupdemonstratingthatpathologicalneoangiogen-
esis and its association with abnormal blood ﬂow patterns within
a tumor is ineffective to support tissue oxygenation (Goel et al.,
2011).
Angiogenesishasbeendemonstratedtooccurinallograftswith
evidence of chronic rejection in association with allograft vas-
culopathy (Atkinson et al., 2005). Similar to our studies in the
huSCID (discussed above), as well as those reported by Babu
et al. (2007), increased capillary density within the parenchyma
of cardiac allografts has been found to be associated with T cell
and monocyte inﬁltrates (Tanaka et al., 1994). Also, neovessels
within the intima of large vessels with vasculopathy lesions have
beenfoundtobespatiallyassociatedwithinﬂammatoryinﬁltrates
(Tanaka et al., 1994; Denton et al., 2004). These neovessels within
allograftsareactivated,inasmuchastheyexpresscellsurfaceadhe-
sion molecules and MHC class II. Thus,the angiogenesis reaction
itself may be pro-inﬂammatory in as much as it has potential
to mediate the recruitment and the activation of local inﬁltrates
(Atkinson et al., 2005).
Collectively,theseﬁndingsillustratethatleukocyte-inducedEC
proliferation/angiogenesis occurs at different sites within allo-
grafts.Weproposethattheabnormalangiogenicmicrovasculature
may be causative of disease, and that local tissue hypoxia is the
result, rather than the primary stimulus of the response (Jain,
2005;Figure1).Thisparadigmexplainsinparthowtheintragraft
microenvironment functions to initiate and sustain the develop-
mentofchronicallograftrejection.Othermajorissuesrelatetothe
production of cytokines and growth factors that initiate EndMT,
illustratedinFigure2.Thiswillbediscussedinmoredetailbelow.
OVERLAPPING NATURE OF INFLAMMATION AND
ANGIOGENESIS AND THE DEVELOPMENT OF CHRONIC
REJECTION
During inﬂammation, the leukocyte-induced angiogenesis reac-
tionmaybeassociatedwithlocalareasof tissuehypoxiaandtissue
injury (illustrated in Figure 1). To this end, it is important to
notethatangiogenesisfactorssuchasVEGFhavebeenreportedto
be overexpressed in all models of chronic inﬂammation, includ-
ing models of chronic rejection, and their expression has been
found to be associated with disease progression (Leibovich et al.,
1987; Folkman and Brem,1992; Cotran,1994; Majno,1998; Ezaki
et al.,2001; Ferrara,2005). Consistent with this possibility,block-
ade of individual angiogenesis factors, including VEGF–VEGFR
interactions, in animal models has been found to attenuate the
progression of the chronic rejection disease process (Lemstrom
et al., 2002; Nykanen et al., 2003; Reinders et al., 2003a; Denton
et al.,2004; Sho et al.,2005; Malmstrom et al., 2008).
On the other hand,immune inﬂammation and the angiogene-
sis response can be antagonistic. For instance, some angiogenesis
factors such as ﬁbroblast growth factor (FGF) may inhibit adhe-
sionmoleculeexpressionandhaveanti-inﬂammatoryeffects(Jain
et al., 1996; Melder et al., 1996). Some inﬂammatory mediators
such as IFNγ or the IFNγ-inducible chemokine CXCL10/IP-10
canbeanti-angiogenic(Strieteretal.,1995a;Bouldayetal.,2006).
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Moreover, the competitive binding of chemokines to their recep-
tors (and vice versa) results in competition for angiogenesis and
inﬂammation(Strieteretal.,1995b).So,howisitpossiblethatthe
evolution of the leukocyte-induced angiogenesis response can be
associatedwithpro-inﬂammation?Neovesselsatsitesofangiogen-
esisexpressadhesionmoleculesandchemokinesandcanfacilitate
the recruitment of leukocytes in part via enhanced leukocyte–
endothelial adhesion events (Melder et al., 1996; Detmar et al.,
1998; Kim et al.,2001; Reinders et al.,2003a). In addition,media-
torsoftheleukocyte-inducedangiogenesisreaction,suchasVEGF,
induce the expression of EC adhesion molecules [including E-
selectin, ICAM-1, and VCAM-1 (Melder et al., 1996; Kim et al.,
2001)]andpro-inﬂammatorychemokines[suchasCXCL10/IP-10
and MCP-1 (Marumo et al., 1999; Reinders et al., 2003a; Boulday
et al., 2006)]. Also, as will be discussed below, VEGF can serve
as a potent leukocyte chemoattractant via direct interactions with
its receptors expressed on subsets of monocyte/macrophages and
T cells (Barleon et al., 1996; Shin et al., 2009; Basu et al., 2010;
Suzuki et al., 2010). Therefore, once established within allografts,
the initial EC activation response that results in proliferation and
angiogenesis also facilitates inﬂammation. In contrast,inﬂamma-
tory mediators can both stimulate and inhibit angiogenesis. Thus,
the balance between the relative production of pro- versus anti-
angiogenic factors in the course of the immune response will
determine the inducible neovascular response, resulting in vas-
cular repair or injury, and this process may be a key determinant
of the outcome of rejection.
Collectively, these observations suggest that the overlapping
nature of inﬂammation and angiogenesis create an environ-
ment that is critical to shape the rejection process. They also
imply that pharmacologic manipulation of the EC response to
injury or leukocyte-induced angiogenesis will target the patho-
logical intragraft microenvironment and interrupt chronic rejec-
tion. Indeed, in animal models, several angiogenesis inhibitors
have been reported to slow the progression of chronic rejec-
tion (Lemstrom et al., 2002; Denton et al., 2004; Reinders et al.,
2006; Malmstrom et al., 2008). PTK787, a selective VEGFR pro-
tein tyrosine kinase angiogenesis inhibitor was found to attenuate
the development of interstitial ﬁbrosis and allograft vasculopathy
in well-established rat cardiac and renal transplantation models
(Lemstrom et al.,2002; Malmstrom et al.,2008).Also,TNP-470,a
syntheticfumagillinderivativeandawell-establishedangiogenesis
inhibitor was found to interrupt the progression of inﬂamma-
tion, intragraft ﬁbrosis, and the degree of allograft vasculopathy
in the Fischer 344 into Lewis rat cardiac allograft model (Denton
et al., 2004). Furthermore, we ﬁnd that endostatin, another well-
establishedangiogenesisinhibitorpreventstheprogressionofallo-
graft vasculopathy in the MHC class II mismatched B6.C-H2bm12
into C57BL/6 mouse model of chronic rejection (Contreras and
Briscoe, unpublished observations). Therefore, it appears that
transient interruption therapy with angiogenesis inhibitors has
potential to normalize the vasculature and inhibit the progression
of chronic rejection.
To this end, it is important to note that the mTOR kinase
and its associated signaling pathway has profound effects on EC
proliferation in vitro and in vivo (Dormond et al., 2007; Contr-
eras et al., 2008). We believe that mTOR inhibitors represent the
ﬁrst-in-kindangiogenesisinhibitoragentsthatarecurrentlybeing
used therapeutically in humans following transplantation. Fur-
thermore, we suggest that this biological effect may account for
some of their ability to retard the progression of chronic rejec-
tion (Contreras et al., 2008). Several reports have indicated that a
switch from calcineurin inhibitor therapy to an mTOR inhibitor
based regimen (interruption protocol) in humans slows the pro-
gressionof chronicrejection(Oberbaueretal.,2005;Schenaetal.,
2009;Arora et al.,2011). These observations support the possibil-
ity that angiogenesis inhibitors have potential as therapeutics in
the future.
ENDOTHELIAL CELL TO MESENCHYMAL TRANSITION:
POSSIBLE FINAL END RESULT OF LEUKOCYTE-INDUCED OR
PATHOLOGICAL ANGIOGENESIS
The Kalluri group demonstrated that EC within cardiac allo-
grafts appear to undergo a process of mesenchymal transition to
ﬁbroblastsinassociationwithinﬂammationandchronicrejection
(Zeisbergetal.,2007a).Thisprocess,calledEndMTbyseverallab-
oratories results from the dedifferentiation of EC, such that they
lose their endothelial phenotype and gain the expression of mes-
enchymal markers (illustrated in Figure 2). In this manner, the
process of EndMT is characterized by the loss of well-established
EC molecules including CD31 and CD34, and the gain in expres-
sion of ﬁbroblast-speciﬁc protein 1 (FSP1), alpha-smooth muscle
actin (Zeisberg et al.,2007a,b),as well as other non-EC molecules
(Kokudo et al., 2008). In vitro, it is reported, that EndMT occurs
in response to both TGFβ1( Arciniegas et al., 1992) and TGFβ2
(Medici et al., 2010), but the stimuli for mesenchymal transition
in vivo are poorly understood. The process of EndMT occurs in
association with pericyte loss, when EC are denuded from their
basement membrane. Denuded EC and pericytes migrate into the
surrounding tissue, where they are exposed to TGFβ that may
be produced locally by multiple cell types and/or delivered into
the graft by monocyte/macrophages (Jain et al., 2002; Booth and
Bishop,2010),thus leading to their differentiation into ﬁbroblasts
(illustrated in Figure 2).
Endothelial-to-mesenchymal transition is well-established to
occur during embryonic development of the heart, in normal
wound healing and in several different cancers (Markwald et al.,
1975;Zeisbergetal.,2007b).Ithasalsobeenimplicatedinchronic
ﬁbroticdiseasestatesincludingatherosclerosis,pulmonaryhyper-
tension,cardiacﬁbrosis,anddiabeticnephropathy(Zeisbergetal.,
2007a; Li et al., 2009; Hashimoto et al., 2010). In cancer, EndMT
has been reported to account for up to 40% of cancer-associated
ﬁbroblasts, and the process has been found to alter the microen-
vironment in several ways (Zeisberg et al., 2007b). EC that have
undergone EndMT produce collagen,deposit extracellular matrix
molecules, and secrete pro-ﬁbrotic factors including TGFβ, lead-
ing to a self-perpetuating cycle of events. In contrast, its role in
allograft rejection has not been well characterized, and it remains
controversial whether EndMT is primarily related to pericyte loss
and their migration into the local tissue, or whether it is truly
related to EC dedifferentiation (Humphreys et al., 2010). Regard-
lessof whetherthepericyteand/ortheECdedifferentiatesintothe
collagen-producing cell, the process, and long-term consequence
of microvascular destruction is ﬁbrosis.
www.frontiersin.org April 2012 | Volume 3 | Article 54 | 5Bruneau et al. The intragraft microenvironment
Since the intragraft microenvironment has similarities to
the tumor microenvironment (i.e., abnormal microvessels, local
hypoxia,TGFβ, highVEGF, mononuclear cell inﬁltrates), we have
speculated that pathological and/or leukocyte-induced angiogen-
esiswillprecedeEndMTwithinallografts(illustratedinFigure2).
Consistent with this possibility,proliferating EC have been shown
to be associated with alloimmune targeting and chronic rejec-
tion (Sis et al., 2009; Osasan et al., 2011). In addition, we have
foundthatproliferatingECaremostsusceptibletoEndMTinvitro
in the presence of inﬂammatory cytokines, TGFβ, and hypoxia.
In contrast, we ﬁnd that EC that have not undergone multiple
rounds of proliferation are not as susceptible to EndMT (Woda
and Briscoe, unpublished observations). It will be important to
understand if intragraft cytokines or growth factors that acti-
vate EC can initiate this pathological process and how VEGF
functions in the EndMT process. An alternate hypothesis is that
the intragraft cytokine milieu and/or hypoxia within allografts
at times of leukocyte-induced angiogenesis alters pericyte biol-
ogy which becomes a central determinant of both the loss of the
microvasculature and differentiation into ﬁbroblasts. Thus, there
is a need for research in this area as it is a potential target of future
therapeutics.
VASCULAR ENDOTHELIAL GROWTH FACTOR: A CENTRAL
PLAYER IN THE CHRONIC REJECTION INTRAGRAFT
MICROENVIRONMENT
Bydeﬁnition,thedevelopmentof acuteallograftrejectioninvolves
a marked inﬂammatory reaction, characterized by the recruit-
ment of leukocytes and an intense cellular and humoral attack
on the graft (Ingulli et al., 2009). By contrast, chronic rejection is
a more insidious process involving delayed type hypersensitivity
mechanisms and is characterized by mononuclear cell inﬁltra-
tion, an obliterative vasculopathy, and progressive ﬁbrosis (Libby
and Pober, 2001; Ingulli et al., 2009). Over the past 10–15years,
VEGFhasemergedasanimportantplayerintherejectionprocess,
and its expression has been reported by several groups to be
associated with both acute and chronic allograft rejection (Torry
et al., 1995; Pilmore et al., 1999; Lemstrom et al., 2002; Rein-
ders et al., 2003b, 2006; Malmstrom et al., 2008). In one study
(Pilmore et al., 1999), VEGF expression was found to be most
striking in the interstitium of human renal allografts in associa-
tion with CD68+ monocyte/macrophage inﬁltrates and evidence
of chronic rejection. In another study (Torry et al., 1995), the
expression of VEGF was found to be associated with ﬁbrin depo-
sition, and was conﬁned to areas with monocyte/macrophage
inﬁltrates.Inourownanalyses,weobservedintenseVEGFexpres-
sion within human cardiac allografts localized to both inﬂam-
matory cell inﬁltrates as well as to vascular EC in association
with acute and chronic rejection (Reinders et al., 2003b). More-
over, we found that persistent intragraft VEGF overexpression
identiﬁed patients at high risk for the development of chronic
allograft vasculopathy/chronic rejection (Reinders et al., 2003b).
Furthermore,human transplant recipients with genotypes encod-
ing high VEGF production are at increased risk for the devel-
opment of rejection (Shahbazi et al., 2002; Girnita et al., 2008).
Levels of VEGF increase signiﬁcantly in the serum and urine of
patients in association with cardiac and renal allograft rejection
respectively, and in most cases return to baseline after effective
treatment of the rejection episode (Abramson et al., 2002; Peng
et al., 2008). It is thus possible that serum levels of VEGF may
serve as a reliable biomarker of the development of allograft vas-
culopathy following human cardiac transplantation (Daly et al.,
2011).
VEGFmaybedeliveredintoallograftsinthecourseof rejection
byinﬁltratingmonocytesandbyactivatedTcells(Leibovichetal.,
1987; Leibovich and Wiseman, 1988; Freeman et al., 1995; Melter
et al., 2000). Alternatively, VEGF may be induced locally within
the allograft as a result of cellular interactions among activated
platelets and EC (Chiodoni et al., 2006; Dormond et al., 2008).
Nevertheless, the local overexpression of VEGF within allografts
resultsinthedevelopmentofchronicrejectionandallograftvascu-
lopathy (Lemstrom et al.,2002). Taken together,there is extensive
data to support the hypothesis that VEGF is mechanistic in the
process of chronic allograft rejection.
The major stimulus for VEGF expression is hypoxia (Shweiki
et al., 1992; Mukhopadhyay et al., 1995; Goel et al., 2011), but
other factors that can upregulate local tissue VEGF production
includeparacrineeffectsofhormones,glucoseandprostaglandins,
as well as cytokine/growth factor modulators of protein kinase
C, nitric oxide, and stimulators of adenylate cyclase (Brown
et al., 1997). Several cytokines, including IL-1, TNF, and IL-
6, have been found to induce the expression of VEGF and/or
VEGF receptors (Leibovich et al., 1987; Giraudo et al., 1998;
Amano et al., 2004; Huang et al., 2004). In addition, we have
demonstrated that the ligation of CD40 by CD154 (CD40 lig-
and, expressed by activated platelets and T cells) is potent for
local tissue induction of VEGF expression (Melter et al., 2000;
Dormond et al., 2008). In this manner, it is not surprising that
cell-mediated immune inﬂammation is associated with VEGF–
VEGFR biological responses. Furthermore, since multiple VEGF-
inducing factors are present within allografts at different times
post transplantation, one might conclude that VEGF expression,
and VEGF-dependent biological responses should be characteris-
tic features of both the initiation and the maintenance of chronic
rejection.
BIOLOGY OF VEGF–VEGFR INTERACTIONS
Asitsnamesuggests,VEGFclassicallyfunctionsasapotentangio-
genesis factor, and as such it was originally proposed to facili-
tate microvascular repair following ischemic injury (Kang et al.,
2001a,b; Mayer, 2011) as well as injury following inﬂammatory
insults (Choi et al., 2000; Reinders et al., 2006). VEGF is a 45-
kDa protein produced by most cell types including cells of the
immune system such as monocyte/macrophages and activated T
cell subsets (Freeman et al., 1995; Brown et al., 1997; Polverini,
1997; Melter et al.,2000; Basu et al.,2010). It is a heparin-binding
homodimeric glycoprotein with several protein variants of 206,
189, 164, 145, and 121 amino acids that arise from the alternative
splicing of a single gene (Leung et al., 1989; Tischer et al., 1991).
Intense research beyond the scope of this review, has clariﬁed the
function of VEGF in EC, where it mediates migration, growth,
survivalaswellasactivationresponsesincludingtheexpressionof
adhesion molecules and chemokines (Alon et al.,1995; Klagsbrun
andD’Amore,1996;Melderetal.,1996;Brownetal.,1997;Gerber
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et al., 1999; Kim et al., 2001; Ferrara, 2005; Boulday et al., 2006;
Lee et al., 2007).
The biological activities of VEGF are mediated via interactions
with its receptors, Flt-1 (VEGF receptor 1), KDR (VEGF receptor
2),andneuropilin-1(Shalabyetal.,1995;KlagsbrunandD’Amore,
1996;Brownetal.,1997;MiaoandKlagsbrun,2000;Ferrara,2005;
Takahashi and Shibuya,2005; Matsumoto and Mugishima,2006).
Several studies have shown that signaling mediated via KDR is
critical for the VEGF-induced response (Zeng et al., 2001). For
instance,many of the biological properties of VEGF can be inhib-
ited by neutralization of KDR; and inhibition of KDR has similar
effects as neutralization of VEGF in vivo in inﬂammatory diseases
(Brown et al., 1997; Watanabe et al., 2004, 2005; Ferrara, 2005),
including allograft rejection (Reinders et al., 2003a; Sho et al.,
2005).Also,knockoutofeitherVEGForKDRresultsinembryonic
lethality due to inhibition of angioblast differentiation and vascu-
logenesis (Shalaby et al., 1995; Ferrara et al., 1996). Classically, it
is thought that neuropilin-1 serves as an accessory co-receptor for
KDR to bindVEGF and mediate crosslinking to KDR (Klagsbrun
andD’Amore,1996;MatsumotoandMugishima,2006).However,
some studies have suggested that neuropilin-1 might also mediate
signaling directly in response to the semaphorin 3 family of pro-
teins (Wang et al., 2003; Catalano et al., 2006; Mizui et al., 2009;
Suzuki et al., 2008). VEGF also signals through Flt-1 to initiate a
directsignalingresponse,butitsinteractionwithFlt-1mayinhibit
KDR-induced responses in EC (Zeng et al., 2002). Thus, VEGF
inducible responses in different cells can be determined according
to the proﬁle of expression of its receptors and thus, the select
VEGFR-dependent signal.
All VEGF receptors are expressed by EC, but individual recep-
tors are also expressed by different leukocyte subsets indicating
that VEGF may have direct effects on the immune response (Bar-
leon et al., 1996; Bruder et al., 2004; Sarris et al., 2008; Shin et al.,
2009; Basu et al., 2010; Suzuki et al., 2010). Flt-1 and neuropilin-
1 are expressed by human monocytes and APCs (Barleon et al.,
1996;Romeo et al.,2002;Bourbie-Vaudaine et al.,2006;Chapoval
et al., 2009), and VEGF is known to induce activation responses
andchemotacticactivityinmonocytesinpartviainteractionswith
Flt-1(Barleonetal.,1996;Claussetal.,1996;Laxmananetal.,2005;
Chapoval et al., 2009). VEGF–VEGFR interactions also promote
the differentiation of monocytes into pro-inﬂammatory (Chapo-
val et al., 2009) or immunoregulatory (Gabrilovich et al., 1998;
Laxmanan et al., 2005) APCs, but its effect is likely dependent
on individual VEGFR(s) expressed by the APC (Laxmanan et al.,
2005; Chapoval et al.,2009).
Moreover,several recent studies have indicated that T cell sub-
sets can express VEGFRs, including Flt-1, KDR, and neuropilin-1
(Dias et al., 2000; Tordjman et al., 2002; Mor et al., 2004; Sar-
ris et al., 2008; Basu et al., 2010; Edelbauer et al., 2010; Ziogas
et al., 2011). In our studies (Basu et al., 2010; Edelbauer et al.,
2010), we ﬁnd low negligible levels of expression of all VEGFRs
on freshly isolated populations of unactivated CD4+ and CD8+ T
cells. However, we have observed that the expression of Flt-1 and
KDR increase following mitogen-dependent activation. In addi-
tion, we have found high levels of KDR on memory CD45RO+
populations of CD4+ T cells (Basu et al., 2010). In general, KDR
and Flt-1 are reported to be the dominant VEGFRs expressed on
T effector cells (Basu et al., 2010; Edelbauer et al., 2010; Zhang
et al., 2010; Ziogas et al., 2011). In contrast, it is reported that
neuropilin-1 is selectively expressed at high levels on populations
of CD4+CD25+FoxP3+ T regulatory cells (Bruder et al., 2004;
Sarrisetal.,2008).OnestudyindicatedthatTregulatorycellsmay
also express KDR (Suzuki et al.,2010). Neuropilin-1 has also been
reported to be expressed on populations of human naïve T cells,
where it functions to support the initiation of T cell activation in
primary immune responses (Tordjman et al.,2002).
Collectively, these ﬁndings support the possibility that intra-
graftVEGF may interact with different T cell subsets in the course
of the rejection process.VEGF may function as a potent chemoat-
tractant for effector and memory CD4+ and CD8+ T cells, and
may thus promote inﬂammation in association with acute and
chronic allograft rejection. Consistent with this possibility, the
blockade of VEGF or VEGFR interactions with T cells inhibits
intragraftlymphocytetrafﬁcking(Reindersetal.,2003a;Shoetal.,
2005; Edelbauer et al., 2010; Zhang et al., 2010)a sw e l la sr e a c t i -
vation responses (Basu et al., 2010) in human model systems. In
experimental animal models, the local overexpression of VEGF,
and VEGF–VEGFR interactions also facilitate lymphocyte traf-
ﬁcking (Reinders et al., 2003a; Lee et al., 2004; Kim et al., 2009;
Edelbaueretal.,2010;Zhangetal.,2010)andactivationincluding
the augmentation of Th1 (Chapoval et al., 2009), Th2 (Lee et al.,
2004), and Th17 (Kim et al., 2009) effector responses. The mech-
anism(s) by which local tissue VEGF elicits signals for migration
and activation/reactivation responses is the subject of ongoing
investigations.
PRO-INFLAMMATORY EFFECTS OF VEGF–VEGF RECEPTOR
INTERACTIONS
Asdiscussedabove,VEGFmayactasapro-inﬂammatorycytokine
in vivo in several chronic diseases (Fava et al., 1994; Koch et al.,
1994; Duh andAiello,1999; Ferrara andAlitalo,1999; Griga et al.,
1999;Hoshinoetal.,2001;Kanazawaetal.,2001;McDonald,2001;
Walsh and Pearson, 2001; Kim et al., 2009; Detoraki et al., 2010),
and its ability to function as a pro-inﬂammatory cytokine in part
relates to its interactions with its receptors expressed on leuko-
cytes (Barleon et al., 1996; Shin et al., 2009; Basu et al., 2010;
Edelbauer et al., 2010; Suzuki et al., 2010; Zhang et al., 2010). Its
ability to interact directly with monocytes (via Flt-1), NK T cells,
and CD3+ T cells (via Flt-1 and KDR) to facilitate chemotactic
activity is likely of great pathophysiological importance in rejec-
tion(Edelbaueretal.,2010;Zhangetal.,2010).Inaddition,VEGF
induces the expression of adhesion molecules and chemokines in
EC(Melderetal.,1996;Marumoetal.,1999;Kimetal.,2001;Rein-
ders et al., 2003a; Boulday et al., 2006), and classically enhances
vascular permeability (Brown et al.,1997; Basu et al.,2001).All of
these events are characteristic of acute and chronic inﬂammation
(Cotran, 1994).
In models of chronic rejection, it was demonstrated that
overexpression of VEGF mobilizes bone marrow derived mono-
cyte/macrophages and accelerates the development of allograft
vasculopathy (Lemstrom et al., 2002; Zhao et al., 2002). Further,
it was found that blockade of VEGF receptor 2 (KDR) signaling
decreases monocyte recruitment into vascular lesions and atten-
uates the development of graft arteriosclerosis (Lemstrom et al.,
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2002;Zhaoetal.,2002).WefoundthatKDRisexpressedonCD3+
inﬁltrates within rejecting human allografts in vivo,and that both
anti-VEGF and anti-KDR antibodies inhibit the transmigration
of CD4+ and CD8+ T cells across activated EC using an in vitro
live-time transmigration model (Edelbauer et al., 2010). Using a
huSCID mouse model of lymphocyte trafﬁcking,we also demon-
strated that KDR-expressing lymphocytes migrate into human
skin in vivo, and that migration is reduced in mice treated with
a blocking anti-VEGF antibody (Edelbauer et al., 2010). Collec-
tively, these observations demonstrate that induced expression of
KDR on subsets of T cells, and locally expressed VEGF facilitate
lymphocyte chemotaxis. They support a model whereby intra-
graftVEGF mediates the localization of T cells in association with
chronic rejection.
In another recent report, Zhang et al. (2010) used an anti-
human VEGF antibody to study the effect of VEGF blockade on
the development of allograft vasculopathy in a humanized model
in SCID mice. They found that anti-VEGF inhibited intragraft
accumulationofTcellswithoutaffectingTcellactivation.Inaddi-
tion,theyobservedthatanti-VEGFtreatmentinhibitedneointimal
formation within human coronary artery grafts in the humanized
mouse.TheauthorssuggestedthattheTcellchemoattractiveeffect
of VEGF was mediated in part via interactions with a subpopula-
tion of Flt-1-expressing CD3+ T cells. Thus,intragraftVEGF may
also contribute to vascular remodeling and allograft vasculopathy
by enhancing T cell recruitment into the intima of large vessels.
Collectively, these observations indicate that VEGF has potent
pro-inﬂammatory properties under pathological conditions in
association with the development of chronic rejection and allo-
graft vasculopathy.
OVERALL SUMMARY AND PERSPECTIVE
In this review, we have discussed a paradigm where leukocyte-
inducedangiogenesis,localtissuehypoxia,andtheoverexpression
of VEGF sustain an intragraft microenvironment that fosters the
development of chronic allograft rejection. We have also deﬁned
EC-based events within the allograft microenvironment that are
associated with chronic rejection. The ﬁrst are changes in the
microcirculation resulting from destruction of the microvascu-
lature. The second are changes in the microcirculation resulting
from EC proliferation and leukocyte-induced angiogenesis. Both
events are likely to disrupt normal blood ﬂow patterns within
the graft and result in local areas of tissue hypoxia. In addition,
EC undergoing proliferation express adhesion molecules and
chemokines that support pro-inﬂammation, providing another
mechanism whereby the angiogenesis reaction may sustain ongo-
ing tissue injury.A third intragraft determinant of chronic disease
is the development of EndMT. While the mechanism underly-
ing EndMT is controversial, there is sufﬁcient evidence to suggest
that inﬂammation and EC proliferation is associated with peri-
cyte loss, which likely precedes microvascular capillary loss and
the development of ﬁbrosis. Whether the pericyte or the EC, or
both, ultimately dedifferentiate into collagen-producing cells is
being debated. Nevertheless, it has been reported that cytokines
and growth factors, including TGFβ (Booth and Bishop, 2010),
can accelerate this ﬁbrotic reaction.Although beyond the scope of
thisreview,TGFβmayalsobeakeyaspectof thechronicrejection
intragraftmicroenvironment(Jainetal.,2000).Finally,wepropose
thatafourthandkeydeterminantof chronicrejectionisintragraft
overexpressionofVEGF,whichfunctionstofacilitatebothinﬂam-
mation and pathological EC proliferation/angiogenesis. While
VEGFmaybedeliveredintoallograftsbyinﬂammatoryinﬁltrates,
such as monocytes and activated T cells, the immune response
can also elicit the local overproduction of VEGF within the graft.
Overall, in this review we provide insight into novel aspects of
the intragraft microenvironment that contribute to the develop-
ment of chronic rejection and long-term attrition of allografts
following transplantation. The importance of this paradigm is
that it identiﬁes key areas for future therapeutic targeting to pre-
vent the progression of chronic rejection following solid organ
transplantation.
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